Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

AIFF - Firefly Neuroscience, Inc. So'nggi... | Finranks

Home

AIFF

F

Firefly Neuroscience, Inc. (AIFF)

NCM – Real vaqt narxi. Valyuta: USD

2.18

-0.84 (-27.81%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

2.11

-0.07 (-3.21%)

Bozordan keyin: Mar 27, 2026, 7:59 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Firefly Confirms Public-Private Partnership with the Department of War

Firefly Confirms Public-Private Partnership with the Department of War

Firefly's AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service Members

Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD

Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD

Over 22 million Americans are diagnosed with ADHD — yet an objective biological marker for distinguishing between its three distinct subtypes has, to date, remained elusive 1

What's Going On With Firefly Neuroscience Stock On Friday?

What's Going On With Firefly Neuroscience Stock On Friday?

Firefly Neuroscience Inc. (NASDAQ: AIFF) shares are up on Friday as the company continues to make strides in its development of brain scan technologies.

Firefly Neuroscience Skyrockets — Brain Scan Breakthrough Fuels Rally

Firefly Neuroscience Skyrockets — Brain Scan Breakthrough Fuels Rally

Firefly Neuroscience Inc. (NASDAQ: AIFF) shares are up on Wednesday as the company continues to develop its foundation model of the human brain.

Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration

Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration

- Company reports 20-fold expansion of commercial footprint, 33-fold increase in EEG/ERP brain scan volumes - - Harnessing increased data and cutting-edge supercomputing potentially unlocks new AI-driven biomarker discovery capabilities and significantly advances Firefly on its path of building a foundation model of the human brain - KENMORE, N.Y., March 04, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce a greater than 20-fold expansion of its commercial footprint, and a 33-fold Increase in its EEG/ERP scan volumes.

Firefly Neuroscience Reports Third Quarter 2025 Financial Results

Firefly Neuroscience Reports Third Quarter 2025 Financial Results

– Quarterly performance characterized by higher revenues, reduced cost structure and improved bottom line – – Successful business integration drives 10.9% sequential quarter-over-quarter EEG/ERP scan volumes and 30% sequential revenue growth – KENMORE, N.Y., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today reported financial results for the three and nine months ended September 30, 2025.

Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research

Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research

– Institute of Human Genetics at Heidelberg University Hospital ongoing EEG biomarker study on 15q13.3 CNVs – – Collaboration aims to uncover novel insights into the brain's functional architecture in rare genetic conditions – – Building and growing a license business is an increasingly important pillar of Firefly's commercial strategy – KENMORE, N.Y., July 14, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to highlight its ongoing collaboration with Prof.

Videolar

No Data

There is no data to display

Press-relizlar

Firefly Confirms Public-Private Partnership with the Department of War

Firefly Confirms Public-Private Partnership with the Department of War

Firefly's AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service Members

Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD

13.03.2026

Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD

Over 22 million Americans are diagnosed with ADHD — yet an objective biological marker for distinguishing between its three distinct subtypes has, to date, remained elusive 1

Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration

Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration

- Company reports 20-fold expansion of commercial footprint, 33-fold increase in EEG/ERP brain scan volumes - - Harnessing increased data and cutting-edge supercomputing potentially unlocks new AI-driven biomarker discovery capabilities and significantly advances Firefly on its path of building a foundation model of the human brain - KENMORE, N.Y., March 04, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce a greater than 20-fold expansion of its commercial footprint, and a 33-fold Increase in its EEG/ERP scan volumes.

Firefly Neuroscience Reports Third Quarter 2025 Financial Results

Firefly Neuroscience Reports Third Quarter 2025 Financial Results

– Quarterly performance characterized by higher revenues, reduced cost structure and improved bottom line – – Successful business integration drives 10.9% sequential quarter-over-quarter EEG/ERP scan volumes and 30% sequential revenue growth – KENMORE, N.Y., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today reported financial results for the three and nine months ended September 30, 2025.